{
    "nctId": "NCT02520063",
    "briefTitle": "Combination of Letrozole, Everolimus and TRC105 in Postmenopausal Women With Hormone-Receptor Positive and Her2 Negative Breast Cancer",
    "officialTitle": "A Phase I/II Study of Preoperative (Neoadjuvant) Combination of Letrozole (Femara), Everolimus (Afinitor), and TRC105 in Postmenopausal Women With Newly Diagnosed Local or Locally Advanced Potentially Resectable Hormone-Receptor Positive and Her2 Negative Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1, PHASE2",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 15,
    "primaryOutcomeMeasure": "Number of Participants Who Experienced Dose-limiting Toxicities",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Recent diagnosis of hormone receptor positive and HER2 negative breast cancer.\n* Stage 2 and 3 hormone receptor positive and HER2 negative breast cancer (stage T2-4 but not inflammatory, N0-2, M0).\n* Histological grade I, II or III according to the modified Bloom Richardson scale.\n* No prior treatment specific for breast cancer.\n* Postmenopausal status as defined by the National Comprehensive Cancer Network.\n* ECOG performance status \\< 2 (Karnofsky \\> 60%).\n* Must have signed study-specific informed consent.\n* Liver Function Tests \\< 2.5 times the upper normal limit (UNL).\n* ANC \u2265 1,500/mm3, platelets \u2265 100,000/mm3, Hemoglobin \u2265 10g%.\n* Renal function: serum creatinine \\< 1.5 institutional UNL or creatinine clearance \\> 40 cc/min.\n\nExclusion Criteria:\n\n* Inflammatory breast cancer.\n* Pre- and peri-menopausal state.\n* Pregnancy.\n* Metastatic disease.\n* HER2 positive breast cancer by immunohistochemistry or FISH.\n* Triple negative breast cancer (hormone receptor and Her2 negative).\n* Disease that cannot be followed by imaging studies.",
    "sex": "FEMALE",
    "minimumAge": "19 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}